These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38554057)

  • 1. Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.
    Friedland PL; Tucker S
    Laryngoscope; 2024 Mar; ():. PubMed ID: 38554057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pilot Study of 0.4% Povidone-Iodine Nasal Spray to Eradicate SARS-CoV-2 in the Nasopharynx.
    Sirijatuphat R; Leelarasamee A; Puangpet T; Thitithanyanont A
    Infect Drug Resist; 2022; 15():7529-7536. PubMed ID: 36575672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.
    Zarabanda D; Vukkadala N; Phillips KM; Qian ZJ; Mfuh KO; Hatter MJ; Lee IT; Rao VK; Hwang PH; Domb G; Patel ZM; Pinsky BA; Nayak JV
    Laryngoscope; 2022 Nov; 132(11):2089-2095. PubMed ID: 34724213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro Nasodine Can be an Effective Antibiofilm Agent for Biofilms that May Cause CRS.
    Hale SJM; Lux CA; Kim R; Biswas K; Tucker S; Friedland P; Mackenzie BW; Douglas RG
    Laryngoscope; 2023 Oct; 133(10):2490-2495. PubMed ID: 36644968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
    Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
    Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial.
    Hasan MJ; Rumi SKNF; Banu SS; Uddin AKMN; Islam MS; Arefin MK
    Trials; 2021 Jan; 22(1):2. PubMed ID: 33397432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quadruple blind, randomised controlled trial of gargling agents in reducing intraoral viral load among hospitalised COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial.
    Khan FR; Kazmi SMR; Iqbal NT; Iqbal J; Ali ST; Abbas SA
    Trials; 2020 Sep; 21(1):785. PubMed ID: 32928313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2.
    Frank S; Brown SM; Capriotti JA; Westover JB; Pelletier JS; Tessema B
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1054-1058. PubMed ID: 32940656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of povidone-iodine nasal rinse and mouth wash in COVID-19 management: a prospective, randomized pilot clinical trial (povidone-iodine in COVID-19 management).
    Alsaleh S; Alhussien A; Alyamani A; Alhussain F; Alhijji A; Binkhamis K; Khan A; Javer A; Alshahrani FS
    BMC Infect Dis; 2024 Mar; 24(1):271. PubMed ID: 38429662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the iodine absorption, safety, and tolerability of a 0.5% povidone-iodine nasal spray (Nasodine).
    Friedland PL; Polasek TM; Topliss D
    Int Forum Allergy Rhinol; 2024 Jun; ():. PubMed ID: 38869489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 viral dynamics in a placebo-controlled phase 2 study of patients infected with the SARS-CoV-2 Omicron variant and treated with pomotrelvir.
    Borroto-Esoda K; Wilfret D; Tong X; Plummer A; Kearney B; Kwong AD
    Microbiol Spectr; 2024 Feb; 12(2):e0298023. PubMed ID: 38197702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis of
    Idrees M; McGowan B; Fawzy A; Abuderman AA; Balasubramaniam R; Kujan O
    Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seawater nasal wash to reduce symptom duration and viral load in COVID-19 and upper respiratory tract infections: a randomized controlled multicenter trial.
    de Gabory L; Vallet S; Naelten G; Raherison-Semjen C
    Eur Arch Otorhinolaryngol; 2024 Jul; 281(7):3625-3637. PubMed ID: 38376591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.
    Tandon M; Wu W; Moore K; Winchester S; Tu YP; Miller C; Kodgule R; Pendse A; Rangwala S; Joshi S;
    Lancet Reg Health Southeast Asia; 2022 Aug; 3():100036. PubMed ID: 35784831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing povidone-iodine to reduce the risk of SARS-CoV-2 infection and transmission: a narrative review.
    Lim NA; Teng O; Ng CYH; Bao LXY; Tambyah PA; Quek AML; Seet RCS
    Ann Med; 2022 Dec; 54(1):1488-1499. PubMed ID: 35594333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
    Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
    Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.